Compare Amphastar Pharmaceuticals Inc (AMPH) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs JetBlue Airways Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while JetBlue Airways Corporation trades at $5.74 (market cap $2.14B). The key difference: JetBlue Airways Corporation is far larger — about 2.6× Amphastar Pharmaceuticals Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | JBLU | |
|---|---|---|
Market Cap | $826.08M | $2.14B |
Sector | Health | Industrials |
52-Week High | $30.81 | $6.46 |
52-Week Low | $16.87 | $4.03 |
Enterprise Value | $1.22B | $9.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
JetBlue (JBLU) trades at $5.76, down 2.7% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported a net loss of $602 million in 2025, with negative profit margins and elevated debt levels. Recent news highlights a major Fort Lauderdale expansion, while analyst consensus is predominantly Hold with a $5.12 price target below the current price.
The outlook remains challenging due to persistent losses and high leverage, though expansion efforts and potential fuel cost relief offer some upside. Key risks include volatile oil prices, competitive pressure, and execution of the turnaround strategy. Investors should weigh cost management improvements against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
